Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2025 16:05 ET | Source: Hyperion DeFi, Inc.

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings

LAGUNA HILLS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S....
July 02, 2025 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.

Name change reflects company’s leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol “HYPD” effective...
June 30, 2025 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement

LAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company...
June 25, 2025 08:30 ET | Source: Eyenovia, Inc.

Eyenovia Announces Co-Branded Validator with Kinetiq

LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company...
June 23, 2025 08:30 ET | Source: Eyenovia, Inc.

Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program

The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a validator on Hyperliquid FDA registration...
June 18, 2025 08:32 ET | Source: Eyenovia, Inc.

Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group

LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company...
June 17, 2025 14:55 ET | Source: Eyenovia, Inc.

Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy

Announces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed Chief Investment Officer and Board Member LAGUNA HILLS,...
May 19, 2025 17:30 ET | Source: Eyenovia, Inc.

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the...
April 10, 2025 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging...
March 20, 2025 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform ...